Metrics as of 10/13/2026, 06:55 PM (Berlin time), refresh in progress.
Quantum BioPharma Ltd.
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with…
1D
-4.0%
1W
-11.9%
1M
-19.8%
6M
-9.6%
YTD
-62.0%
1Y
-82.6%
2Y
-42.4%
5Y
-97.0%
10Y
–
Next earnings date
06/11/2026 (in 20 days)
Volatility around earnings
~65% stronger price swings than usual
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
P/E
-0.48
P/B
2.29
EV/EBITDA
-0.63
RETURN ON EQUITY
-39.9%
NET MARGIN
0.0%
DEBT/EQUITY
0.12
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
89.0%
FLOAT SHARES
5,693,376
AVG. DAILY VOLUME (30D)
195,462
Quantum BioPharma Ltd. is a company in the Healthcare sector, Biotechnology industry, headquartered in Canada.
The CEO is Zeeshan Saeed, the company employs around 17 people.
The IPO was on 08/06/2018; the stock trades on NASDAQ under the ticker QNTM.
The next earnings date is 06/11/2026.
Around past earnings, price swings were roughly 65% stronger than usual.
No, Quantum BioPharma currently does not pay a dividend.
Comparable stocks include AbCellera Biologics, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
Clicking "Analyze stock" lets five strategies assess Quantum BioPharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.